IBQ

Zywave Releases 2021 Stewardship Report Highlighting Unparalleled Innovation & Transformational Solutions

Retrieved on: 
星期四, 三月 3, 2022
Carrier, IBQ, P&C, Risk management, Industry, Customer support, Safety, CPQ, Solution, Growth, CEO, Insurance, Health, Association for Corporate Growth, Online shopping, Zywave

MILWAUKEE, March 3, 2022 /PRNewswire/ --Leading insurtech provider, Zywave , today released its 2021 Stewardship Report detailing the company's milestones over the past year.

Key Points: 
  • MILWAUKEE, March 3, 2022 /PRNewswire/ --Leading insurtech provider, Zywave , today released its 2021 Stewardship Report detailing the company's milestones over the past year.
  • Highlights from 2021 include over 500 product releases and enhancements, further expansion in both carrier and P&C markets, and four major corporate acquisitions, reinforcing Zywave's position among the largest platform providers of end-to-end insurance solutions.
  • "Zywave's vision is to revolutionize the insurance market through digital transformation," said Jason Liu, CEO of Zywave.
  • Zywave leads the insurtech industry, fueling business growth for its partners with cloud-based sales management, client delivery, content and analytics solutions.

Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congress

Retrieved on: 
星期一, 十月 4, 2021
Filgotinib, Medicines and Healthcare products Regulatory Agency, Review, Sandborn, TNF, PMDA, European Directive on Traditional Herbal Medicinal Products, Induction, Union, Health care, Methotrexate, Volume Ten, Safety, RA, EQ-5D, EMA, MHRA, Interview, European Medicines Agency, MTX, European, Adult, Work, Disease, Ulcerative colitis, Product, Inflammatory bowel disease, Tablet, Gilead, Inflammatory Bowel Diseases, Inflammation, Ministry of Health, Labour and Welfare, JAK1, Eisai, WPAI, IBQ, Gilead Sciences, Fibrosis, Mayo, MCS, Quality of life (healthcare), Week, Diagnosis, IBD, Galapagos NV, Patient, Disease-modifying antirheumatic drug, CHMP, European Union, Contraindication, Quality of life, Conditional sentence, Pharmaceutical industry, Medical device

In addition to the physical impact from flare ups, there is also a psychological impact associated with UC.

Key Points: 
  • In addition to the physical impact from flare ups, there is also a psychological impact associated with UC.
  • The European Summary of Product Characteristics for filgotinib, which includes contraindications and special warnings and precautions, is available at www.ema.europa.eu .
  • Filgotinib in UC has been filed in the European Union, Great-Britain and Japan, and a global Phase 3 program is ongoing in Crohns Disease.
  • Clinically meaningful improvements in health-related quality of life among patients with ulcerative colitis treated with filgotinib: post hoc analysis of the phase 2b/3 SELECTION study.